Moonlake Immunotherapeutics last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): diluted EPS of -$0.93. It usually reports 35–54 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 22, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Feb 23, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–54 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
—
|
-80
-14.1%
|
-0.93
+15.5%
|
|
Aug 10, 2026
41 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-62
-11.9%
|
-0.84
+3.4%
|
|
May 11, 2026
41 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-70
-74.5%
|
-0.98
-55.6%
|
|
Feb 23, 2026
54 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-62
-36.9%
|
-0.92
-27.1%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-70
-97.0%
|
-1.10
-96.4%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-55
-127.6%
|
-0.87
-123.1%
|
|
May 12, 2025
42 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-40
-192.1%
|
-0.63
-186.4%
|
|
Feb 26, 2025
57 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-46
-513.2%
|
-0.72
-482.2%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MLTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Zug, Switzerland
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1821586
- Former names
- Helix Acquisition Corp (until Mar 31, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.